相关实验视频
Updated: Jun 29, 2025
10:34
A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
7.7K
与阿尔茨海默氏病相关的区域特异性降低膀性谷氨酸载体免疫活性在中部叶和上部回中
Oliver W G Wood1, Josh Walby1, Jason H Yeung1
1Centre for Brain Research and Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
Neuroscience
|March 29, 2024
概括
阿尔茨海默病会影响大脑特定区域的囊泡性谷氨酸转运体 (VGLUTs). 在阿尔茨海默氏症患者中,观察到VGLUT1和VGLUT2表达的变化发生在中间叶和上圈中.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,治疗选择有限.
- 激发性神经递质系统功能障碍,特别是涉及谷氨酸,与AD病变发生有关.
- 膀型谷氨酸转运体 (VGLUTs) 调节谷氨酸的释放,使它们成为潜在的治疗点.
研究的目的:
- 量化和比较VGLUT1和VGLUT2在AD和没有AD的人类脑部关键区域的特定层表达.
- 调查VGLUT表达在中间叶,包括海马体,脑内皮层和脑内皮层,以及上层回.
主要方法:
- 使用自由浮式光免疫组织化学来标记VGLUT1和VGLUT2.
- 激光扫描共聚焦显微镜用于成像.
- 进行了载体密度测量分析,以量化VGLUT表达水平.
主要成果:
- 在AD组织中,VGLUT1密度没有显著的差异,除了在牙状层分子中较低的染色.
- 在海马体和脑内皮层中,VGLUT2的表达没有改变,但在AD病例的脑内皮层和上旋环中显著减少.
结论:
- 阿尔茨海默氏症在中叶和上状圈内表达VGLUT1和VGLUT2的区域特异性变化.
- 需要进一步的研究来阐明这些VGLUT障碍的原因和功能影响,以评估它们的治疗潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184